Brellium, a New York-based AI-powered clinical compliance and revenue integrity platform, has raised $23 million in venture funding. The round was led by Left Lane Capital and First Round Capital, with participation from Digital Health Venture Partners.
The company announced the funding on October 13, 2026, alongside the introduction of CortexLM, its AI-powered clinical chart-auditing system. The investment will support Brellium’s expansion into additional healthcare specialties and further development of its revenue integrity capabilities.
Founded in 2021 by Zach Rosen, Henry Kasa, Alex Le-Tu and Max Katzman, Brellium develops software that helps healthcare organizations automate clinical documentation reviews, identify compliance risks and detect coding issues before medical claims are submitted. Rosen serves as CEO, while Kasa is COO and Katzman leads engineering.
Its CortexLM system examines patient notes against provider-specific clinical, regulatory and payer requirements. The platform identifies potential documentation errors, gaps in care and billing discrepancies, allowing healthcare organizations to address issues before they result in denied claims, repayment demands or compliance problems.
Brellium plans to use the new capital to expand its technology into clinical specialties including cardiology, pain management and primary care. The expansion will extend its existing work with behavioral health organizations and other healthcare providers.
According to the company’s funding announcement, Brellium served more than 215,000 healthcare providers across over 200 provider groups in all 50 US states. Its customers include healthcare organizations such as Headspace, Rula, Gentiva and Maxim Healthcare.
Brellium also reported that its technology had audited approximately 22 million patient visits and helped protect nearly $2 billion in provider revenue from potential recoupments.
The financing follows Brellium’s $16.7 million Series A round announced in April 2025, which was backed by First Round Capital and Left Lane Capital, alongside Menlo Ventures.
